

# Thursday 11 March

1330 - 1500

Hall

## *Clinical Studies And Ethics*

Chair

001/ OR1

Time	Title	Poster Board Number	Abstract Number	Reference IC
	LECTURES FOR CLINICAL STUDIES AND ETHICS TBA		9440.00	8511
1500	COFFEE BREAK		9001.00	8511

1530 - 1700

Hall

## *Ophthalmology Drugs - Market Analysis*

Chair

005/ OR2

Time	Title	Poster Board Number	Abstract Number	Reference IC
	LECTURES FOR OPHTHALMIC DRUGS - MARKET ANALYSIS TBA		9441.00	8511

**Friday 12 March**0900 - 0945 Hall***Update on Age Related Macular Degeneration  
Satellite Symposium Sponsored by Pfizer****Chair*

010/ OR9

Time	Title	Poster Board Number	Abstract Number	Reference IC
0900	<sup>0</sup> PFIZER MACULAR DEGENERATION ABSTRACTS			8511
			9207.00	

0900 - 0945 Hall***Blood Flow****Chair*

015/ OR3

Time	Title	Poster Board Number	Abstract Number	Reference IC
0900	<sup>0</sup> THE IMPORTANCE OF BLOOD FLOW IN THE MANAGEMENT OF GLAUCOMA A.Harris, USA (*)		9020.00	7600
0915	<sup>0</sup> VASCULAR ENDOTHELIAL FUNCTION IN GLAUCOMA C.O'Brien, Ireland (*)		2027.00	5402
0930	<sup>0</sup> OPTIC NERVE BLOOD FLOW AFTER ACUTE INTRAOCULAR PRESSURE RISE IN RABBIT A.Tomidokoro, Japan (*) ; J.Takayama ; M.Araie		1018.00	7738

0945 - 1030 Hall***Satellite Symposium Sponsored by MSD****Chair*

020/ OR10

Time	Title	Poster Board Number	Abstract Number	Reference IC
0945	<sup>0</sup> GLAUCOMA PROGRESSION: BEYOND IOP A.Harris, USA (*)		2046.00	7600
1000	<sup>0</sup> 24-HOUR IOP AND BLOOD PRESSURE CONTROL: A NEW CLINICAL CHALLENGE L.Quaranta, Italy (*)		2042.00	5547
1015	<sup>0</sup> EFFECTING OCULAR BLOOD FLOW A.Martinez, Spain (*)		2047.00	8485
1030	<sup>0</sup> COFFEE BREAK		9002.00	8511

0945 - 1030 Hall***Genetics: Basic Concepts For Clinicians****Chair*

025/ OR4

Time	Title	Poster Board Number	Abstract Number	Reference IC
0945	<sup>0</sup> TBA A.Aurichio		90210.00	465
1000	<sup>0</sup> GENE THERAPY IN GLAUCOMA: WILL IT REPLACE DRUGS AND SURGERY? P.Kaufman, USA (*)		1152.00	4716
1015	<sup>0</sup> GENETIC MODELS OF MACULAR DEGENERATION: WHAT DO WE KNOW AND WHAT DO WE NEED TO KNOW J.Ambati, USA (*)		1195.00	443
1030	<sup>0</sup> COFFEE BREAK		9000.00	8511

**Friday 12 March****1100 - 1145** **Hall*****Prostaglandins In The Eye  
Satellite Symposium Sponsored by Pfizer****Chair*

035/ OR11

Time	Title	Poster Board Number	Abstract Number	Reference IC
1100	0 THE EFFICACY AND MECHANISM OF ACTION OF PROSTAGLANDIN ANALOGUES P.Kaufman, USA (*)		1151.00	4716
1115	0 PERSISTENCY OF TREATMENT WITH GLAUCOMA THERAPY W.Stewart, USA (*)		1052.00	6015
1130	0 WHEN MONOTHERAPY IS NOT ENOUGH J.Thygesen, Denmark (*)		2038.00	6102

**1100 - 1145** **Hall*****Infection****Chair*

037/ OR5

Time	Title	Poster Board Number	Abstract Number	Reference IC
1100	0 INTRODUCTION T.O'Brien, USA (*)		9022.00	5405
1106	0 LASA PROTEASE AS A THERAPEUTIC AGENT IN STAPHYLOCOCCAL KERATITIS  I.Barequet, Israel (*) ; Y.Pessach, Israel ; G.Ben Simon, Israel ; M.Safrin, Israel ; M.Rosner, Israel ; E.Kessler, Israel		2045.00	1166
1119	0 COMPARISON OF MINIMAL INHIBITORY AND MUTANT PREVENTION DRUG CONCENTRATION OF VARIOUS FLUOROQUINOLONES AGAINST OCULAR ISOLATES: A STRATEGY FOR MINIMIZING THE EMERGENCE AND SPREAD OF ANTIMICROBIAL RESISTANCE J.Blondeu, Canada (*)		2026.00	8445
1132	0 CLASS PRESERVATION STRATEGIES G.Tillotson, USA (*)		9023.00	8446

**1145 - 1230** **Hall*****IOP Lowering Agents****Chair*

040/ OR12

Time	Title	Poster Board Number	Abstract Number	Reference IC
1145	0 THE CORNEAL THICKNESS IN GLAUCOMA STUDIES J.Jonas, Germany (*)		9209.00	6411
1200	0 THE SIGNIFICANCE OF DIURNAL VARIATION OF IOP P.Netland, USA (*)		2019.00	7739
1215	0 DRUG MODULATION OF THE TRABECULAR MESHWORK J.Thygesen, Denmark (*)		2037.00	6102
1230	0 LUNCH		9004.00	8511

**Friday 12 March**1145 - 1230 Hall**Biologicals**

Chair

045/ OR6

Time	Title	Poster Board Number	Abstract Number	Reference IC
1145	0 INTRODUCTION C.Foster, USA (*)		90240.00	8439
1148	0 ZENAPAX THERAPY FOR UVEITIS R.Nussenblatt, USA (*)		1165.00	5355
1201	0 THE CLINICAL USE OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR OCULAR INFLAMMATION E.Kim, USA (*) ; C.Foster		2015.00	8424
1214	0 EMERGING BIOLOGIC THERAPIES FOR IMMUNE-MEDIATED DISEASES J.Rosenbaum, USA (*)		1172.00	5645
1227	0 SUMMARY AND CONCLUSIONS D.Jabs, USA (*)		9205.00	8096
1230	0 LUNCH		9003.00	8511

1300 - 1415 Hall**Poster Session 1**

Chair

050/ PO3

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	EFFECT OF BIMATOPROST ON OCULAR CIRCULATION IN OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSIVE PATIENTS C.Akarsu, Turkey (*) ; S.Yilmaz, Turkey ; P.Taner, Turkey ; A.Ergin, Turkey		1016.00	8139
0	EFFECTS OF BRINZOLAMIDE ON OCULAR HEMODYNAMICS IN HEALTHY VOLUNTEERS O.Arend, Germany (*) ; M.Kaup, Germany ; N.Plange, Germany ; M.Niegel, Germany ; A.Remky, Germany		1035.00	69
0	FIBRIN GLUE AS A SUTURE SUBSTITUTE: HISTOLOGICAL EVALUATION OF TRABECULECTOMY IN RABBIT EYES I.Bahar, Israel (*) ; D.Weinberger ; M.Lusky ; R.Avisar ; A.Robinson ; D.Gaton		1112.00	1148
0	IMPACT OF DAILY INTRA-OCULAR PRESSURE VARIABILITY ON PRESCRIPTION DECISIONS: A MODELING APPROACH H.DuBiner, USA ; G.Berdeaux, France (*)		1085.00	8222
0	BETA-BLOCKERS EFFECTS ON RETINAL BLOOD FLOW AND CONTRAST SENSITIVITY IN POAG PATIENTS B.Brogliatti, Italy (*) ; L.Belli ; F.Tofani ; B.Roagna ; G.Vizzeri ; T.Rolle		1118.00	8340
0	THE EFFECTS ON IOP AND PULSATILE OCULAR BLOOD FLOW OF BIMATOPROST IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA SWITCHED FROM TIMOLOL M.Vetrugno ; N.Cardascia (*) ; L.Arnese ; F.Cantatore ; C.Sborgia		1021.00	8157
0	BLOOD-AQUEOUS BARRIER CHANGES FOLLOWING THE USE OF PROSTAGLANDIN ANALOGUES IN PSEUDOPHAKIC AND APHAKIC PATIENTS E.Arcieri, Brazil ; V.Costa, Brazil (*) ; A.Santana, Brazil ; F.Rocha, Brazil		1101.00	1921
0	GLAUCOMA EXAMINED BY 30 HZ FLICKER MULTIFOCAL ERG M.Danielczyk, Germany (*) ; M.Bullin, Germany ; K.Hoerauf, Austria ; R.Welt, Germany		1082.00	8220
0	TREATMENT FOR GLAUCOMA: A COST-UTILITY ANALYSIS C.Eandi, Italy (*) ; F.Fronticelli ; F.Tofani ; B.Brogliatti ; F.Grignolo		1053.00	2550
0	IOP AND RETINAL ARTERIOLE REACTIVITY TO NO MODULATORS: AN "IN VIVO" STUDY		1044.00	8198

**Friday 12 March**

1300 - 1415

Hall

**Poster Session 1**

Chair

050/ PO3

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	M.Gaspar, Portugal (*) ; I.Lapa, Portugal ; J.Frade, Portugal ; C.Ribeiro, Portugal ; T.Macedo, Portugal ; J.Cunha-Vaz, Portugal EFFECT OF ORAL DONEPEZIL, A SELECTIVE ACETYLCHOLINE-ESTERASE-INHIBITOR, ON INTRAOCULAR PRESSURE IN NORMOTENSIVE ALZHEIMER PATIENTS		1100.00	3497
0	D.Goldblum, Switzerland (*) ; S.Estermann, Switzerland ; G.Daepf, Switzerland ; O.Meier, Switzerland ; K.Aebi, Switzerland ; M.Berkhoff, Switzerland ; B.Frueh, Switzerland THE LATANOPROST MONOTHERAPY AND COMBINATION THERAPY WITH TIMOLOL-GEL		1062.00	8177
0	T.Hara, Japan (*) ; T.Hashimoto ; T.Tsuru USAGE OF ANTIMETABOLITES IN CONGENITAL GLAUCOMA SURGERY		1105.00	8298
0	R.Harutunyan, Armenia (*) STRUCTURAL CHANGES IN THE OPTIC DISC AFTER MEDICAL TREATMENT WITH LATANOPROST		1067.00	8205
0	P.Hentova/Sencanic, Yugoslavia (*) ; M.Milovic DORZOLAMIDE/TIMOLOL FIXED COMBINATION VERSUS LATANOPROST: EFFECTS ON INTRAOCULAR PRESSURE AND HEMODYNAMICS		1045.00	8199
0	I.Januleviciene, Lithuania (*) ; A.Harris, USA ; L.Kagemann, USA ; B.Siesky, USA ; L.McCranor, USA GLAUCOMA SUSPECTS, MANIFEST OAG, AND A FAMILY HISTORY, IDENTIFIED BY NEW PUPILLOGRAPHIC TEST		1148.00	8357
0	G.Kandel, USA (*) ; M.Kabeck, USA ; R.Sanchez, USA CONTRIBUTION OF RTA AND OCT IN DIAGNOSING PRE-PERIMETRIC AND EARLY GLAUCOMA		2017.00	8484
0	A.Kaplan-Messas, Israel (*) ; N.Benhamou ; I.Avni "EFFICACY AND SAFETY OF BRIMONIDINE 0.2% IN POAG-AS PRIMERY (MONO), REPLEACEMENT AND ADJUNCTIVE (TIMOLOL .5%) THERAPY. IN INDIAN SCENIERO - A 3 MONTHS STUDY"		1183.00	8432
0	A.Khueta, India (*) ; P.Mathur DOES THERAPY WITH DORZOLAMIDE EYE DROPS AFFECT RETINAL VESSEL THICKNESS CHANGE FREQUENCY IN GLAUCOMA PATIENTS?		1142.00	8354
0	K.Kotliar, Germany (*) ; W.Vilser, Germany ; E.Nagel, Germany ; I.Lanzl, Germany APPLICATION OF XALATAN TO PATIENTS WITH GLAUCOMA AND MYOPIA		1113.00	8303
0	N.Makashova, Russia (*) DOES LATANOPROST HAVE A DESENSITIZING EFFECT ON THE CONJUNCTIVAL HYPEREMIA ASSOCIATED WITH SUBSEQUENT TREATMENT WITH BIMATOPROST		1027.00	8168
0	S.Kurtz ; O.Man (*) ; M.Lazar EFFECTS OF TOPICAL UNOPROSTONE ON CIRCULATION IN THE OPTIC NERVE HEAD AND RETINA OF RABBITS		1119.00	8341
0	C.Mayama, Japan (*) ; M.Ohashi, Japan ; K.Ishii, Japan ; A.Tomidokoro, Japan ; M.Araie, Japan ROLE OF LYSOPHOSPHOLIPID GROWTH FACTORS AND EDG RECEPTORS IN THE MODULATION OF AQUEOUS HUMOR OUTFLOW FACILITY		1104.00	8287
0	P.Mettu, USA (*) ; P.Deng, USA ; U.Misra, USA ; G.Gawdi, USA ; D.Epstein, USA ; P.Rao, USA CHANGES OF THE RETINAL NERVE FIBER THICKNESS AFTER REDUCING INTRAOCULAR PRESSURE WITH LATANOPROST		1068.00	8206
0	M.Milovic, Yugoslavia (*) ; P.Hentova-Sencanic EFFECTS OF NYOLOL GEL ON PLASMA LIPID PROFILES IN GLAUCOMA PATIENTS		1155.00	8382
0	M.Regenbogen, Israel (*) ; M.Neudorfer ; G.Shemesh ; S.Kurtz RETINAL OXYGEN SATURATION IN PATIENTS WITH POAG		1111.00	7576
0	M.Scibor, Germany (*) ; G.Michelson, Germany ; D.Schweitzer, Germany ; M.Hammer, Germany ; D.Baleanu, Germany			

**Friday 12 March**1300 - 1415 Hall**Poster Session 1**

Chair

050/ PO3

Time	Title	Poster Board Number	Abstract Number	Reference IC
	; R.Lammer, Germany ; J.Harazny, Germany			
0	BRINZOLAMIDE 1% VERSUS DORZOLAMIDE 1% IN ADDITION TO THE COMBINATION THERAPY WITH LATANOPROST AND BETA-BLOCKER		1061.00	6128
	H.Tsukamoto, Japan (*) ; H.Noma, Japan ; T.Soeda, Japan ; E.Ue, Japan ; H.Mishima, Japan ; H.Ikeda, Japan			
0	WATER-DRINKING TEST IN PATIENTS AFFECTED BY PRIMARY OPEN-ANGLE GLAUCOMA UNDER SEVERAL TYPES OF TOPICAL MEDICATIONS		1019.00	6163
	M.Vetrugno, Italy (*) ; D.Sisto, Italy ; T.Trabucco, Italy ; F.Balducci, Italy ; N.Delle Noci, Italy ; C.Sborgia, Italy			
29	EFFICACY OF LATANOPROST VERSUS TIMOLOL MALEATE IN AFRICAN-AMERICAN PATIENTS COMPARED WITH CAUCASIAN PATIENTS		2020.00	7739
	N.Kitnarong, USA ; A.Kent ; Y.Zhao, USA ; P.Netland, USA (*)			
1300	EMGT CRITERIA COMPARED WITH CLINICAL ASSESSMENT FOR VISUAL FIELD PROGRESSION		1127.00	8347
	L.Naveh, Israel (*) ; R.Ehrlich, Israel ; D.Gaton, Israel ; M.Calev, Israel			

1330 - 1415 Hall**Poster Session 2**

Chair

055/ PO1

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	MORPHOLOGICAL ASPECTS OF AUTOIMMUNE NEUROPROTECTION BY GLATIRAMER ACETATE (COP-1) IN A RAT MODEL OF CHRONICALLY INDUCED HIGH INTRAOCULAR PRESSURE		2024.00	8490
	E.Aloni, Israel (*) ; S.Bakalash, Israel ; G.Ben-Simon, Israel ; A.Pollack, Israel ; M.Schwartz, Israel			
0	CATARACTOGENIC RISKS OF GLYPHOSATE (HERBICIDE)		1110.00	8302
	C.Asonye, Nigeria (*) ; E.Nwanze, Nigeria ; G.Agu, Nigeria			
0	HUMAN LENS EPITHELIAL CELLS (HLE B-3) ACQUIRE IMMORTALITY AND PROLIFERATE IN AN ANCHORAGE-INDEPENDENT MANNER UPON TRANSFECTION WITH GLUTATHIONE S-TRANSFERASE A4-4		1020.00	7613
	Y.Awasthi, USA (*) ; R.Sharma, USA ; D.Brown, USA ; S.Awasthi, USA ; Y.Yang, USA ; A.Sharma, USA ; M.Saini, USA ; P.Zimniak, USA ; S.Singh, USA			
0	COPOLYMER-1 VACCINATION REGIMENS FOR NEUROPROTECTION IN LASER-INDUCED RETINAL INJURIES		1036.00	7662
	M.Belokopytov, Israel (*) ; G.Dubinsky ; Y.Epstein ; M.Belkin ; M.Rosner			
0	CANNABIDIOL INHIBITS VASCULAR PERMEABILITY BREAKDOWN AND REDUCES NEURAL CELL APOPTOSIS IN EXPERIMENTAL DIABETES		1136.00	1844
	G.Liou, USA ; A.El-Remessy, USA ; M.Al-Shabrawey, USA ; N.Tsai, USA ; P.Roon, USA ; R.Caldwell, USA (*)			
0	RIBOFLAVIN IN OPHTHALMOLOGIC MIGRAINE		1022.00	6536
	S.Chowdhury (*)			
0	PHARMACOLOGICAL STUDY OF OPHTHALMIC LIPOSOMAL EMULSION OF QUERCETIN IN TREATMENT OF EYE ANTERIOR PART INFLAMMATION AND CORNEA TRAUMA		1047.00	8201
	A.Grigroryeva, Ukraine (*) ; N.Konakhovich, Ukraine ; O.Chudinova, Ukraine ; L.Chaika, Ukraine ; Y.Krasnopolskiy, Ukraine			
0	PREVENTATIVE EFFECT OF DEFEROXAMINE ON DEGENERATIVE CHANGES IN THE OPTIC NERVE IN EXPERIMENTAL RETROBULBAR HAEMATOMA		1007.00	8094
	G.Haciyakupoglu, Turkey (*) ; A.Pelit, Turkey ; S.Zorludemir, Turkey ; U.Mete, Turkey ; K.Daglioglu, Turkey ; M.Kaya, Turkey			
0	A STUDY ON PROLIFERATION OF VASCULAR ENDOTHELIAL CELLS BY TRADITIONAL CHINESE MEDICINE BUTTERFLYBUSH FLOWER		1073.00	8210
	C.Jie, China (*) ; J.Gao			

**Friday 12 March****1330 - 1415** **Hall****Poster Session 2**

Chair

055/ PO1

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	SIGNIFICANT RETARDATION OF RETINAL DEGENERATION IN THE RDS MOUSE BY ARTISTICALLY COMPOSED CHINESE MEDICINAL HERBS L.Liang, China (*) ; Z.Zhuang, China ; G.Li, China ; J.Wang, China		1011.00	8125
0	PREVENTIVE EFFECTS OF DISULFIRAM AND AMINOGLUANIDINE ON CATARACT DEVELOPMENT T.Nabekura, Japan (*) ; M.Tomohiro, Japan ; Y.Ito, Japan ; S.Kitagawa, Japan		1037.00	5357
0	NEURONAL SPECIFIC GENE TRANSFER IN THE VISUAL SYSTEM OF RAT X.Wang, Singapore (*) ; S.Wang		1012.00	8137
0	Vitreous Fluid Levels of Amyloid and Tau in Patients with Retinal Diseases S.Yoneda, Japan (*) ; H.Hara, Japan ; R.Yamamoto, Japan ; A.Hirata, Japan ; M.Fukushima, Japan ; Y.Inomata, Japan ; H.Tanihara, Japan		1033.00	8183

**1415 - 1500** **Hall****Poster Discussion 1**

Chair

060/ PO4

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	POSTER DISCUSSION WILL INCLUDE POSTERS FROM FOLLOWING BOARDS:		9451.00	8511
1500	COFFEE BREAK		9006.00	8511

**1415 - 1500** **Hall****Poster Discussion 1**

Chair

065/ PO2

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	POSTER DISCUSSION WILL INCLUDE POSTERS FROM FOLLOWING BOARDS:		9450.00	8511
1500	COFFEE BREAK		9005.00	8511

**1530 - 1700** **Hall****Cutting Edge Imaging Technologies**

Chair

070/ OR13

Time	Title	Poster Board Number	Abstract Number	Reference IC
1530	MULTIMODAL MACULA MAPPING: CHARACTERIZATION OF DIFFERENT PHENOTYPES OF DIABETIC RETINOPATHY J.Cunha-Vaz, Portugal (*) ; R.Bernardes, Portugal		1059.00	1937
1548	CLINICAL APPLICATION OF MULTIPLANAR OCT IN SINGLE OR OVERLAY MODE M.de Smet, The Netherlands (*) ; M.van Velthoven, The Netherlands ; A.Podoleanu, UK ; R.Rosen, USA ; F.Verbraak, The Netherlands		1181.00	7612
1606	SIMULTANEOUS OCT/ICG FLUORESCENCE IMAGING OF THE MACULA R.Rosen, USA (*) ; A.Podoleanu, UK ; G.Dobre, UK ; R.Cernat, UK ; P.Garcia, USA ; J.Pedro, Canada ; J.Rogers, Canada ; R.Weitz, Canada ; T.Muldoon, USA ; J.Walsh, USA		2043.00	7268
1624	NON INVASIVE MULTI PARAMETERS FUNCTIONAL IMAGING OF THE RETINA A.Grinvold, Israel (*)		2011.00	8108
1642	THE 3D RTA ANATOMY IMAGER: NEW PERSPECTIVES ON RETINAL THICKNESS IMAGING		2044.00	7268

**Friday 12 March****1530 - 1700** **Hall*****Cutting Edge Imaging Technologies****Chair*

070/ OR13

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference IC</b>
	R.Rosen, USA (*) ; R.Rosenbaum, USA ; P.Garcia, USA ; J.Rosenthal, USA ; R.Gentile, USA ; T.Muldoon, USA ; J.Walsh, USA			

**1530 - 1700** **Hall*****Uveitis****Chair*

075/ OR7

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference IC</b>
1530	<sup>0</sup> OCULAR INFLAMMATORY DISEASE PREVALENCE A.Heiligenhaus, Germany (*)		9206.00	3768
1541	<sup>0</sup> PREVALENCE OF BLINDNESS DESPITE STEROID THERAPY R.Nussenblatt, USA (*)		1171.00	5355
1552	<sup>0</sup> THE SIDE EFFECTS OF STEROID TREATMENT W.Ayliffe, UK (*)		2033.00	401
1603	<sup>0</sup> IMMUNOMODULATORY THERAPY FOR INFLAMMATORY EXTERNAL EYE DISEASES M.Filipec, Czech Republic (*)		1197.00	38
1614	<sup>0</sup> IMMUNOMODULATORY THERAPY FOR OCULAR INFLAMMATORY DISEASE - LITERATURE REVIEW A.Okada, Japan (*)		1089.00	6666
1625	<sup>0</sup> SIDE EFFECTS OF ORAL CORTICOSTEROIDS AND IMMUNOSUPPRESSIVE DRUG THERAPY FOR OCULAR INFLAMMATION D.Jabs, USA (*)		1179.00	8096
1636	<sup>0</sup> NON-STEROIDAL IMMUNOMODULATORY THERAPY FOR OCULAR INFLAMMATORY DISEASE - IMPEDIMENTS TO PROGRESS C.Foster, USA (*)		1170.00	8439
1647	<sup>0</sup> INFLAMMATORY EYE DISEASES STRATEGIC PLANNING: INTERNATIONAL DATA BASE R.Neumann, Israel (*) ; C.Foster, USA		2054.00	5382

**1700 - 1745** **Hall*****Retina Endpoints****Chair*

080/ OR14

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference IC</b>
1700	<sup>0</sup> OCT FOR OCULAR PHARMACOLOGY P.Rosenfeld, USA (*)		9210.00	7269
1715	<sup>0</sup> METHODS TO COMPARE NEW TECHNOLOGIES TO A GOLD STANDARD R.Zeimer, USA (*)		2000.00	6345
1730	<sup>0</sup> PANEL DISCUSSION		9211.00	8511



**Friday 12 March**

1700 - 1745

Hall

*Neuroprotection (Glaucoma)*

Chair

085/ OR8

Time		Title	Poster Board Number	Abstract Number	Reference IC
1700	0	AUTOANTIBODIES: BIOMARKERS IN GLAUCOMA? F.Grus, Germany (*) ; S.Joachim ; N.Pfeiffer		1164.00	3520
1715	0	GLAUCOMA MEDICAL THERAPY AND NEUROPROTECTION L.Wheeler, USA (*)		1185.00	6228
1730	0	NEUROPROTECTION FOR GLAUCOMA M.Schwartz, Israel (*)		1187.00	7508

**Saturday 13 March**0900 - 0945 Hall***The Current Therapeutic Strategy For Ocular Diseases  
Satellite Sponsored by Senju****Chair*

090/ OR22

Time	Title	Poster Board Number	Abstract Number	Reference IC
0900	0 SAFETY AND EFFICACY OF TOPICAL BEPOTASTINE BESILATE IN CONJUNCTIVAL ALLERGEN CHALLENGE MODEL T.Sekiya, Japan (*) ; E.Takamura, Japan ; T.Terai, Japan ; T.Ogawa, Japan		2022.00	8488
0915	0 SAFETY AND EFFICACY OF TOPICAL DIFLUPREDNATE IN PATIENTS WITH SEVERE ANTERIOR UVEITIS T.Ogawa, Japan (*) ; T.Terai, Japan ; S.Ohno, Japan		1069.00	8207
0930	0 OCULAR HYPOTENSIVE EFFECT OF A NEW "ONCE-DAILY" EYE-DROPS FORMULATION OF 0.5% TIMOLOL (TIMOLAST&#8482;) IN COMPARISON TO TIMOPTOL® 0.5% ADMINISTERED TWICE-DAILY J.Rouland, France (*) ; P.Morel-Mandrino, France ; P.Elena, France ; F.De Gregorio, Italy ; C.Barozzi, Italy ; E.Fedeli, Italy ; V.Ferreira, Italy		1051.00	8276

0900 - 0945 Hall***Inhibition of Angiogenesis****Chair*

095/ OR15

Time	Title	Poster Board Number	Abstract Number	Reference IC
0900	0 PATHOGENESIS OF ANGIOGENESIS A.Das, USA (*)		1144.00	2345
0909	0 ANGIOSTATIC EFFECTS OF CYCLOOXYGENASE INHIBITORS IN VITRO AND IN VIVO J.Penn, Tennessee (*) ; D.Bingaman, USA		1088.00	8135
0918	0 INHIBITION OF ANGIOGENESIS BY PREVENTING VESSEL LOSS: INSULIN-LIKE GROWTH FACTOR (IGF-1) / PLGF-1 L.Smith, USA (*)		1153.00	8111
0927	0 STEMMING VISION LOSS WITH STEM CELLS M.Friedlander, USA (*)		1161.00	2853
0936	0 USING RIBOZYMES TO STUDY THE PATHWAY OF ANGIOGENESIS IN RETINOPATHY OF PREMATURITY M.Grant, USA (*) ; L.Shaw ; P.Spoerri ; A.Afzal ; H.Pan		1055.00	3507

0945 - 1030 Hall***Ocular Inflammation  
Sponsored Symposium by Bausch & Lomb****Chair*

100/ OR23

Time	Title	Poster Board Number	Abstract Number	Reference IC
0945	0 INTRODUCTION		9124.00	8511
0950	0 FLUOCINOLONE ACETONIDE (FA) INTRAVITREAL IMPLANT FOR POSTERIOR UVEITIS TBA		9224.00	8511
1000	0 FA IMPLANT FOR TREATMENT OF DIABETIC MACULA EDEMA TBA		9125.00	8511
1010	0 EFFECT OF PRESERVISION ON PATIENTS WITH AMD (AGE RELATED EYE DISEASE STUDY) TBA		9300.00	8511
1020	0 THE EFFECT OF LOTEMAX ON PATIENTS WITH DRY EYE TBA		9301.00	8511

**Saturday 13 March**0945 - 1030 Hall***Ocular Inflammation  
Sponsored Symposium by Bausch & Lomb****Chair*

100/ OR23

Time	Title	Poster Board Number	Abstract Number	Reference IC
1030	0 COFFEE BREAK			8511
			9008.00	

0945 - 1030 Hall***Glaucoma Endpoints****Chair*

105/ OR16

Time	Title	Poster Board Number	Abstract Number	Reference IC
0945	0 DIAGNOSTIC TOOLS AS PART OF DRUG EVALAUTION IN GLAUCOMA O.Arend, Germany (*) ; A.Remky, Germany		1034.00	69
1010	0 PANEL DISCUSSION D. GARWAY-HEATH, O. AREND, R. WEINREB, S. KRUPSKY		9212.00	8511
1030	0 COFFEE BREAK		9007.00	8511

1100 - 1230 Hall***Current And Future Trends In CNV Management  
Satellite Symposium Sponsored by Novartis****Chair*

110/ OR24

Time	Title	Poster Board Number	Abstract Number	Reference IC
1100	0 INTRODUCTION OF CO-CHAIR AND PANEL		9303.00	5301
1105	0 FROM EARLY INNOVATION TO CURRENT EXPERIENCE - THE CASE FOR VISUDYNE THERAPY U.Schmidt-Erfurth, Germany (*)		2049.00	8190
1125	0 REFINING MANAGEMENT OF CNV DUE TO AMD - MAXIMISING PATIENT TREATMENT BENEFIT THROUGH PROMPT AND APPROPRIATE TREATMENT J.Monés, Spain (*)		2048.00	5301
1135	0 CONTINUING INNOVATION WITH VISUDYNE COMBINATION WITH TRIAMCINOLONE: INTERESTING INSIGHT P.Kaiser, USA (*)		2050.00	7029
1145	0 VISUDYNE - CASE STUDY EXAMPLES G.Soubrane, France (*)		9302.00	8264
1155	0 LUCENTIS: A NOVEL ANTIANGIOGENIC THERAPY FOR CNV IN AMD L.Damico, USA (*)		2052.00	8507
1205	0 LUCENTIS: RESULTS FROM PHASE I/II STUDIES P.Rosenfeld, USA (*) ; .Ranibizumab Study Group		2051.00	7269
1220	0 QUESTIONS FROM THE AUDIENCE G. SOUBRANE AND J. MONES		9304.00	8511
1230	0 LUNCH		9010.00	8511

**Saturday 13 March**1100 - 1145 Hall***Ocular Allergy***

Chair

115/ OR17

Time	Title	Poster Board Number	Abstract Number	Reference IC
1100	0 Ocular Allergic Diseases TBA		9213.00	8511
1115	0 Cells, Mediators and Cytokines and their importance in Ocular Allergy N.Barney, USA (*)		9214.00	8338
1130	0 Current Therapeutic Approach S.Bonini, Italy (*)		9215.00	1230

1145 - 1230 Hall***Ocular Surface Disease/ Dry Eyes***

Chair

120/ OR18

Time	Title	Poster Board Number	Abstract Number	Reference IC
1145	0 New Therapeutic Approaches for the Treatment of Dry Eye Syndromes D.Sullivan, USA (*)		1162.00	8098
1158	0 Tear Substitutes: Past, Present and Future P.Asbell, USA (*)		1199.00	456
1206	0 Blepharitis and the Ocular Surface A.Bron, UK (*)		1169.00	7615
1214	0 Mucins and the Ocular Surface D.Kellerman, USA (*)		1160.00	7622
1222	0 New Diagnostic Tests for Dry Eye Disease - Panel Discussion		9216.00	8511
1230	0 Lunch		9009.00	8511

1330 - 1415 Hall***Poster Session 3***

Chair

125/ PO7

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	Inhibiting NADPH oxidase activity blocks VEGF over-expression and prevents retino-vitreous neovascularization M.Al-Shabrawey, USA ; M.Bartoli, USA ; D.Platt, USA ; A.El-Remessy, USA ; S.Matragoon, USA ; R.Caldwell, USA ; R.Caldwell, USA (*)		1139.00	1843
0	Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival C.Cursiefen, UK (*) ; C.Lu, UK ; D.M. Reza, UK ; J.David, UK ; W.Stanley, USA ; S.J. Wayne, UK		2035.00	1825
0	Preclinical studies of squalamine lactate (MSI-1256F) for the inhibition of intraocular neovascularization R.Danis, USA (*) ; K.Holroyd, USA ; M.McLane, USA ; G.Peyman, USA ; R.Higgins, USA ; J.Williams, USA		2012.00	2339
0	Intravitreal triamcinolone as an adjuvant in diffuse diabetic macular edema M.De la Fuente-Torres, Mexico (*) ; I.Velasco-Fuentes ; E.Ortiz-Guzman		1094.00	2350
0	Protection of retinal cells against age- and ROS- induced damages by blockers of carboanhydrase		1066.00	7620

**Saturday 13 March**

1330 - 1415

Hall

**Poster Session 3**

Chair

125/ PO7

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	R.Funk, Germany (*) ; F.Reber ; A.Steinberg ; N.Özkucur ; E.Kniep MICROPLASMIN-INDUCED POSTERIOR VITREOUS DETACHMENT A.Gandorfer, Germany (*) ; A.Kampik, Germany ; P.Luthert, UK ; D.Charteris, UK		1032.00	3031
0	INTRAVITREAL INJECTION OF 2 MG VERSUS 4 MG TRIAMCINOLONE FOR DIFFUSE DIABETIC MACULAR EDEMA - SHORT TERM RESULTS D.Hauser, Israel (*) ; A.Bukelman ; A.Len ; R.Thein ; E.Aloni ; A.Pollack		1184.00	8457
0	PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION USING POLYION COMPLEX MICELLE R.Ideta, Japan (*) ; F.Tasaka, Japan ; Y.Yanagi, Japan ; Y.Tamaki, Japan ; K.Kataoka, Japan		1057.00	8279
0	DURATION OF THE EFFECT OF INTRAVITREAL TRIAMCINOLONE ACETONIDE AS TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA B.Kamppeter, Germany (*) ; J.Jonas ; R.Degenring ; I.Kreissig ; I.Akkoyun		1098.00	8284
0	SCLERAL BUCKLING WITH BIOABSORBABLE POLY-L/D LACTIDE IMPLANT S.Länsman, Finland (*) ; A.Karttunen, Finland ; H.Hirvelä, Finland ; J.Palosaari, Finland ; M.Kellomäki, Finland ; V.Ellä, Finland ; P.Törmälä, Finland ; T.Waris, Finland ; N.Ashammakhi, Finland		1138.00	8350
0	ANTIANGIOGENIC EFFECTS OF PROTEIN KINASE CK2 INHIBITORS AND OCTREOTIDE IN MOUSE OXYGEN-INDUCED RETINOPATHY A.Ljubimov, USA (*) ; S.Caballero, USA ; L.Pinna, Italy ; M.Grant, USA		1141.00	8353
0	PHARMACOLOGIC AND LASER PHOTOCOAGULATION TREATMENT OF CHOROIDAL NEOVASCULAR MEMBRANES (CNV). A PILOT STUDY F.Mandelblum, Venezuela (*) ; D.Tovar, Venezuela ; E.McCormick, Venezuela ; E.Murcia, Venezuela		1117.00	8339
0	EFFECT OF INTRAVENOUS PROSTAGLANDIN E1 IN THE PATIENTS WITH BRANCH RETINAL ARTERY OCCLUSION H.Masuda, Japan (*) ; A.Ohira ; M.Tanito		1116.00	8188
0	PHOTODYNAMIC THERAPY INDUCES MACULAR EDEMA S.Mennel, Germany (*) ; J.Schmidt ; C.Meyer ; E.Rodrigues		2023.00	8489
0	COST-EFFECTIVENESS OF PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION M.Potter, Canada (*) ; S.Szabo		1198.00	5536
0	PERFLUOROCARBON PERFUSED VITRECTOMY (PCPV) H.Quiroz-Mercado, Mexico (*) ; J.Guerrero-Naranjo, Mexico ; R.Agurto-Rivera, Mexico ; L.Suarez-Tata, Mexico ; G.Reategui, Mexico ; C.Leizaola-Fernandez, Mexico ; G.Garcia, Mexico ; S.Charles, USA		1192.00	6681
0	EFFECTS OF HIGH DOSE AND MULTI-DAY METHYLPREDNISOLONE THERAPY ON REPAIR OF LASER-INDUCED RETINAL INJURY S.Schuschereba, USA (*) ; B.Stuck, USA ; J.Marshall, UK		1076.00	8211
0	CALCIUM DOBESILATE (DOXIUM) IN BLOOD-RETINAL BARRIER PERMEABILITY IN EARLY DIABETIC RETINOPATHY A.Seres, Hungary (*) ; G.Coza, Switzerland ; A.Zourdani, France ; M.Stur, Austria		1081.00	8219
0	TARGETED INHIBITION OF VEGF164 ABROGATES RETINAL NEOVASCULARIZATION BUT SPARES NORMAL VESSEL DEVELOPMENT D.Shima, USA (*) ; K.Nishijima, USA ; N.Jo, USA ; S.Ishida, USA ; T.Usui, USA ; K.Yamashiro, USA ; Y.Ng, USA ; A.Adamis, USA		1143.00	8355
0	EFFECT OF TNF-A INHIBITOR ON DIABETIC MACULAR EDEMA D.Skondra, Greece (*) ; M.Karavellas ; M.Tsilimbaris ; I.Pallikaris		1150.00	8371
0	USE OF LIPOIC ACID IN PATIENTS WITH DIABETES AFTER PANRETINAL LASER COAGULATION R.Skripnik, Ukraine ; M.Sydorova (*)		1056.00	6026
0	THE INFLUENCE OF EPITALON ON FREE RADICAL OXIDATION IN CAMPBELL RATS		1013.00	6119

**Saturday 13 March**1330 - 1415 Hall**Poster Session 3**

Chair

125/ PO7

Time	Title	Poster Board Number	Abstract Number	Reference IC
	S.Trofimova, Russia (*) ; V.Khavinson			

1330 - 1415 Hall**Poster Session 4**

Chair

130/ PO5

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	A NON-RANDOMIZED COMPARISON OF THE CLINICAL OUTCOME OF OCULAR INVOLVEMENT IN PATIENTS WITH MUCOUS MEMBRANE (CICATRICAL) PEMPHIGOID BETWEEN CONVENTIONAL IMMUNOSUPPRESSIVE AND INTRAVENOUS IMMUNOGLOBULIN (IVIG) THERAPIES E.Letko, USA ; E.Miserocchi, USA ; Y.Doud, USA ; W.Christen, USA ; A.Ahmed, USA (*)		1097.00	8283
0	TOPICAL ANTI-INFLAMMATORY THERAPY IN PAEDIATRIC OPHTHALMOLOGY G.Bellizzi, Italy (*) ; M.Bellizzi		1115.00	7588
0	THE DISRUPTION OF BLOOD-AQUEOUS BARRIER IN EP2 RECEPTOR KNOCKOUT MICE P.Bhattacharjee, USA (*) ; S.Biswas, USA ; C.Paterson, USA ; S.Tilley, USA ; B.Koller, USA		1135.00	1207
0	EFFICACY OF OPHTHALMIC EPINASTINE FOR RELIEF OF ALLERGIC CONJUNCTIVITIS SYMPTOMS S.Bonini, Italy (*)		1131.00	1230
0	HEALING IN WHOLE ENUCLEATED PIG EYES - AN EX VIVO MODEL J.Garweg, Switzerland (*) ; F.Flueckiger, Switzerland ; M.Boehnke, Switzerland		1108.00	8300
0	FURTHER OCULAR STUDIES WITH NEEM+ OIL - A NEWER NATURAL FORMULATION WITH ANTIMICROBIAL POTENTIAL S.Ghose, India (*) ; N.Biswas, India ; N.Nayak, India ; G.Das, India ; S.Sen, India ; A.Ravi, India ; T.Velpandian, India ; S.Kumari, India ; M.Saxena, India ; A.Srivastava, India		1091.00	3143
0	THERAPEUTIC AND PROPHYLACTIC EFFECT OF THE APPLICATION OF LEVOFLOXACIN 0.5% OPHTHALMIC SOLUTION (OFTA QUIX) IN OCULAR TRAUMA CASES R.Hristova, Bulgaria (*) ; K.Georgiev ; I.Kuneva-Purvanova ; T.Pancheva		2014.00	8482
0	ORAL TOLERISATION WITH PEPTIDE 336-351 LINKED TO CHOLERA TOXIN B SUBUNIT IN PREVENTING RELAPSES OF UVEITIS IN BEHCET'S DISEASE T.Lehner, England (*) ; M.Stanford, England ; T.Whittall, England ; L.Bergmeier, England ; S.Lundin, Sweden ; T.Shinnick, USA ; Y.Mizushima, Japan ; J.Holmgren, Sweden		1159.00	7454
0	PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN VITRO AND INTERLEUKIN-2 SECRETION IN UVEITIC PATIENTS M.Misiuk-Hojlo, Poland ; J.Rusiecka, Poland (*) ; E.Urban, Poland		1014.00	8216
0	TO STUDY THE SAFETY AND EFFICACY OF TRYPAN BLUE IN UVEITIC CATARACT SURGERY A.Sachdev, UK (*) ; S.Thomas ; K.Sabri		1072.00	8209
0	THE RESULTS OF REGULATORY PEPTIDE IMUNOFAN IN THE CHRONIC PEDIATRIC ENDOGENOUS UVEITIS THERAPY T.Sidorova, Russia (*) ; L.Katargina, Russia ; V.Lebedev, Russia		1137.00	8349
0	EVALUATION OF THE ANTIBACTERIAL ACTIVITY OF KOLANONE AND THE BIFLAVONOIDS OF GARCINIA KOLA SEED E.Uzodike, Nigeria (*) ; O.Akano		1046.00	8200
0	POOR QUALITY CONTROL OF INDIAN GENERIC CIPROFLOXACIN EYEDROPS CONTRIBUTES TO DRUG RESISTANCE MECHANISMS R.Weir, UK (*) ; F.Zaidi, UK ; D.Charteris, UK ; C.Bunce, UK ; A.Lovering, UK		1041.00	8194
0	VARIABILITY IN THE CONTENT OF INDIAN GENERIC CIPROFLOXACIN EYEDROPS		1060.00	8194

**Saturday 13 March**1330 - 1415 Hall**Poster Session 4**

Chair

130/ PO5

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	R.Weir, UK (*) ; F.Zaidi, UK ; D.Charteris, UK ; C.Bunce, UK ; M.Soltani, UK ; A.Lovering, UK DANGERS OF MULTIPLE USE OF MINIMAL PRESERVATIVE FREE EYEDROPS IN APPLANATION TONOMETRY		2018.00	80
0	R.Wong, UK (*) ; M.Qureshi, UK ; C.Rowe, UK ; J.Leach, UK LOW CONCENTRATIONS OF INDIAN GENERIC CHLORAMPHENICOL EYEDROPS MAY CONTRIBUTE TO ANTIMICROBIAL RESISTANCE		1122.00	8344
6	F.Zaidi, UK (*) ; R.Weir, UK ; A.Velayudhan, UK ; M.Soltani, UK ; J.Nash, UK ; N.Lovering, UK EYE ALLERGY IMPACT QUESTIONNAIRE (EAPIQ) RESPONSES OF PATIENTS TREATED WITH OPHTHALMIC EPINASTINE		1130.00	1230
	S.Bonini, Italy (*) ; J.Walt, USA ; P.Buchholz, Germany ; M.Fsadni, UK			

1415 - 1500 Hall**Poster Discussion 3**

Chair

135/ PO8

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	POSTER DISCUSSION WILL INCLUDE POSTERS FROM FOLLOWING BOARDS:		9455.00	8511

1415 - 1500 Hall**Poster Discussion 4**

Chair

140/ PO6

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	POSTER DISCUSSION WILL INCLUDE POSTERS FROM FOLLOWING BOARDS:		9453.00	8511
1500	COFFEE BREAK		9012.00	8511

1500 - 1630 Hall**Drug Delivery**

Chair

145/ OR25

Time	Title	Poster Board Number	Abstract Number	Reference IC
1500	0 RECENT ADVANCES IN OCULAR DRUG DELIVERY F.Behar-Cohen, France (*)		2028.00	1185
1515	0 FORMULATION OF HYDROGELS FOR PROMOTING WOUND HEALING AFTER REFRACTIVE SURGERY P.Furrer, Switzerland (*) ; G.Paladino, Italy ; M.Mazzone, Italy ; R.Gurny, Switzerland		1149.00	2994
1530	0 DEVELOPMENT OF UNIL088, A CYCLOSPORINE A PRODRUG FOR TOPICAL DELIVERY TO THE EYE F.Lallemant, Switzerland (*) ; O.Felt-Baeyens, Switzerland ; P.Furrer, Switzerland ; S.Rudaz, Switzerland ; K.Beseghir, Switzerland ; J.Dumont, Switzerland ; F.Behar-Cohen, France ; R.Gurny, Switzerland		1038.00	4857
1545	0 SCLERAL IMPLANTS: A POTENTIAL ROUTE OF ADMINISTRATION? O.Felt-Baeyens, Switzerland (*) ; S.Eperon, Switzerland ; P.Mora, Switzerland ; S.Sagodira, France ; P.Breton, France ; Y.Guex-Crosier, Switzerland ; R.Gurny, Switzerland		1071.00	2941
1600	0 OPHTHALMIC DRUG DELIVERY : QUO VADIS ? B.Plazonnet, France (*)		1175.00	5470
1615	0 OCULAR DRUG DELIVERY BY CATIONIC EMULSIONS S.Benita, Israel (*) ; G.Lambert, France		1166.00	8414

**Saturday 13 March****1500 - 1630** **Hall*****Drug Delivery****Chair*

145/ OR25

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference IC</b>
	S.Benita, Israel (*) ; G.Lambert, France			

**1530 - 1615** **Hall*****Diabetic Macular Edema****Chair*

150/ OR19

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference IC</b>
1530	<sup>0</sup> POSTURDEX FOR DME B.Kuppermann, USA (*)		9217.00	4777
1539	<sup>0</sup> FLUOCINOLONE IMPLANT FOR DME M.Ip, USA (*)		2032.00	7007
1548	<sup>0</sup> MACUGEN FOR DME S.Schwartz, USA (*)		9218.00	7296
1557	<sup>0</sup> RANIBIZUMAB FOR DME TBA		9219.00	8511
1606	<sup>0</sup> PKCBETA INHIBITION FOR DME L.Aiello, USA (*)		9220.00	6712

**1615 - 1700** **Hall*****Progression To PDR****Chair*

155/ OR20

<b>Time</b>	<b>Title</b>	<b>Poster Board Number</b>	<b>Abstract Number</b>	<b>Reference IC</b>
1615	<sup>0</sup> ANTIANGIOGENIC EFFICACY OF CORTICOSTEROIDS R.Danis, USA (*)		2003.00	2339
1624	<sup>0</sup> FLUOCINOLONE IMPLANT R.Danis, USA (*)		9221.00	2339
1633	<sup>0</sup> PCKBETA INHIBITION OF NPDR PROGRESSION AND VISUAL LOSS L.Aiello, USA (*)		9222.00	6712
1642	<sup>0</sup> OCTREOTIDE M.Grant, USA (*)		9223.00	3507
1651	<sup>0</sup> MASKED PILOT STUDY: INTRAVITREOUS HYALURONIDASE (VITRASE) EFFECT ON PROGRESSION OF DIABETIC RETINOPATHY IN HUMANS E.Thomas, USA (*) ; B.Kuppermann, USA ; H.Quiroz Mercado, Mexico ; F.Graue-Weichers, Mexico ; L.Grillone, USA		2030.00	6101



**Saturday 13 March**

1630 - 1715

Hall

*Satellite Symposium Sponsored by Allergan*

Chair

160/ OR26

Time	Title	Poster Board Number	Abstract Number	Reference IC
1630	<sup>0</sup> PATHOPHYSIOLOGY AND TREATMENT OF DRY EYE E.Donnenfeld, USA (*)		9320.00	8444
1640	<sup>0</sup> EMERGING TREATMENT IN DRY EYE J.Tauber, USA (*)		9321.00	8136
1650	<sup>0</sup> OVERVIEW OF TREATMENT AND DIAGNOSIS OF GLAUCOMA R.Weinreb, USA (*)		9322.00	8513
1700	<sup>0</sup> PIVOTAL TRIALS S.Gandolfi, Italy (*)		9333.00	3029
1710	<sup>0</sup> DISCUSSION		9334.00	8511

1700 - 1745

Hall

*Targeting the Vitreous*

Chair

165/ OR21

Time	Title	Poster Board Number	Abstract Number	Reference IC
1700	<sup>0</sup> OVINE HYALURONIDASE UNDER INVESTIGATION FOR VITREOUS HEMORRHAGE: INTEGRATED PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED TRIAL RESULTS B.Kuppermann, USA (*) ; E.Thomas, USA ; J.Chandler, USA ; L.Grillone, USA		2031.00	4777
1709	<sup>0</sup> PLASMIN FOR VITREOLYSIS M.Trese, USA (*)		1092.00	7372
1718	<sup>0</sup> VITREOSOLVE FOR VITREOLYSIS H.Quiroz-Mercado, Mexico (*) ; R.Romero-Castro, Mexico ; D.Ochoa-Contreras, Mexico ; J.Rivera-Sempértegui, Mexico ; H.Karageozian, USA		1124.00	6681
1727	<sup>0</sup> VITREOLYSIS/ POSTERIOR VITREOUS SEPARATION INDUCED BY MICROPLASMIN M.de Smet, The Netherlands (*) ; C.Valmaggia, The Netherlands ; M.Karmel, The Netherlands ; J.Zarrantz, The Netherlands ; B.Willikens, The Netherlands		1191.00	7612
1736	<sup>0</sup> RIBOZYME (VIT100) TO PROLIFERATING CELL NUCLEAR ANTIGEN FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY N.Mandava, USA (*) ; G.Lin, USA ; .VIT100 Study Group, USA		1178.00	7118

**Sunday 14 March**0900 - 1030 Hall**Angiogenesis Inhibition Treatments**

Chair

170/ OR32

Time	Title	Poster Board Number	Abstract Number	Reference IC
0900	0 MACUGEN FOR AMD S.Schwartz, USA (*)		9341.00	7296
0915	0 RANIBIZUMAB (LUCENTIS) FOR AMD P.Rosenfeld, Florida (*) ; R.Study Group, USA		2039.00	7269
0930	0 ANECORTAVE ACETATE FOR CHOROIDAL NEOVASCULARIZATION IN EXUDATIVE AGE RELATED MACULAR DEGENERATION (AMD) P.Kaiser, USA (*) ; P.Zilliox, USA ; S.Robertson, USA ; A.Davis, USA ; .Anecortave Acetate Study Group, USA		1120.00	7029
0945	0 PEDF FOR AMD W.L., USA (*)		1158.00	57
1000	0 A PHASE I/II TRIAL OF INTRAVENOUS SQUALAMINE LACTATE INFUSION FOR TREATMENT OF CHOROIDAL NEOVASCULARIZATION (CNV) ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION (ARMD) H.Quiroz-Mercado, Mexico (*) ; C.Garcia, USA ; S.Uwaydat, USA ; R.Sepulveda-Flores, USA ; A.Meza-de Regil, Mexico ; K.Holroyd, USA ; A.Desai, USA ; S.Solis, Mexico ; L.Estrada, Mexico ; G.Peyman, USA		1132.00	6681
1015	0 RETINOIC ACID FOR AMD E.De Juan, Jr., USA (*) ; J.Lim ; M.Mahmoud ; S.Sadda ; C.Flaxel ; M.Humayun		1147.00	8086
1030	0 COFFEE BREAK		9014.00	8511

0900 - 0945 Hall**Neuroprotection of Ocular Diseases**

Chair

175/ OR27

Time	Title	Poster Board Number	Abstract Number	Reference IC
0900	0 NEUROPROTECTION OF CONES IN ROD-CONE DEGENERATIONS J.Sahel, France (*) ; T.Léveillard, France ; S.Mohand-Said, France ; D.Hicks, France ; S.Picaud, France ; A.Fintz, France ; M.Delyfer, France		2036.00	8496
0910	0 CHARACTERISATION OF NEUROTROPHIC FACTOR SIGNALLING MECHANISMS AND NEUROPROTECTIVE EFFECTS IN IDENTIFIED RETINAL CELLS IN VITRO D.Hicks, France (*) ; E.Vecino, Spain ; J.Sahel, France		1015.00	4150
0920	0 TOWARDS DEVELOPMENT OF A VACCINATION FOR GLAUCOMA M.Schwartz, Israel (*)		1167.00	7508
0930	0 OPTIC NEURITIS TBA		9335.00	8511
0940	0 DISCUSSION		9336.00	8511

**Sunday 14 March**0945 - 1030 Hall***Ocular Toxicology****Chair*

180/ OR28

Time	Title	Poster Board Number	Abstract Number	Reference IC
0945	0 TRENDS IN NONCLINICAL OCULAR TOXICOLOGY-AN INDUSTRY PERSPECTIVE B.Short, USA (*) ; A.Oyejide, USA ; K.Tarlo, USA		2010.00	8128
0955	0 REGULATORY AFFAIRS W.Chambers, USA (*)		9337.00	1873
1005	0 TRENDS CLINICALLY F.Fraunfelder, USA (*)		9338.00	8073
1015	0 DISCUSSION		9339.00	8511
1030	0 COFFEE BREAK		9013.00	8511

1100 - 1145 Hall***PDT New Drugs****Chair*

185/ OR33

Time	Title	Poster Board Number	Abstract Number	Reference IC
1100	0 EFFICACY RESULTS OF TWO PHASE III TRIALS OF SNET2 PHOTODYNAMIC THERAPY FOR AGE-RELATED MACULAR DEGENERATION E.Thomas, USA (*)		2053.00	6101
1110	0 ICG MEDIATED PHOTOTHROMBOSIS FOR THE MANAGEMENT OF PREDOMINANTLY CNV DUE TO AMD M.Farah, Brazil (*) ; J.Cardillo, Brazil ; A.Luzardo, Brazil ; D.Calucci, Brazil ; G.Williams, USA ; R.Costa, Brazil		1194.00	6583
1120	0 PDT/STEROID/DRUG COMBO P.Kaiser, USA (*)		9343.00	7029
1130	0 RETINAL PROTECTION FROM COLLATERAL DAMAGE FROM PDT J.Burke, USA (*)		9345.00	1103
1140	0 DISCUSSION		9426.00	8511

1100 - 1145 Hall***Antioxidants****Chair*

190/ OR29

Time	Title	Poster Board Number	Abstract Number	Reference IC
1100	0 EFFECT OF NEW QUINOLONES ON BLUE LIGHT INDUCED LIPID PEROXIDATION IN PORCINE RETINAL HOMOGENATE T.Nakanishi-Ueda, Japan (*) ; S.Shimada, Japan ; T.Ueda, Japan ; S.Uchida, Japan ; N.Mochizuki, Japan ; R.Koide, Japan ; H.Yasuhara, Japan		1079.00	5364
1115	0 INTENSIFICATION OF THIOREDOXIN, AN ENDOGENOUS REDOX REGULATOR, AGAINST LIGHT INDUCED RETINAL DAMAGE M.Tanito, Japan (*)		1070.00	8179
1130	0 THE EMERGING ROLE OF CAROTENOIDS IN THE TREATMENT AND PREVENTION OF AGE-RELATED MACULAR DEGENERATION P.Bernstein, USA (*)		1049.00	8171

**Sunday 14 March**1145 - 1230 Hall***Triamcinolone Acetonide***

Chair

195/ OR34

Time	Title	Poster Board Number	Abstract Number	Reference IC
1145	0 TRIAMCINOLONE FOR DME R.Danis, USA (*)		9427.00	7029
1154	0 TRIAMCINOLONE ACETONIDE FOR CHOROIDAL NEOVASCULARIZATION DUE TO AMD R.Danis, USA (*)		2004.00	2339
1203	0 HIGH-DOSE INTRAVITREAL TRIAMCINOLONE FOR TREATMENT OF INTRAOCULAR NEOVASCULAR AND EDEMATOUS DISEASES J.Jonas, Germany (*) ; I.Kreissig ; R.Degenring		1176.00	6411
1212	0 INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSION M.Ip, USA (*) ; J.Gottlieb, USA ; A.Kahana, USA ; I.Scott, USA ; M.Altaweel, USA ; B.Blodi, USA ; R.Gangnon, USA ; C.Puliafito, USA		1196.00	7007
1221	0 PERIOcular VERSUS INTRAVITREAL TRIAMCINOLONE FOR UVEITIC CME C.Pavesio, UK (*)		2007.00	5499
1230	0 LUNCH		9016.00	8511

1145 - 1230 Hall***Apoptosis***

Chair

200/ OR30

Time	Title	Poster Board Number	Abstract Number	Reference IC
1145	0 IN-VIVO IMAGING OF AMYLOID IN EYES AND BRAINS OF CHRONIC OCULAR HYPERTENSION (COH) RATS S.McKinnon, USA (*) ; L.Kasmala, USA ; H.Kung, USA		1102.00	8285
1200	0 APOPTOSIS SIGNALING PATHWAYS IN SERUM DEPRIVED AND GLUTAMATE INDUCED CYTOTOXICITY OF RGC-5 RAT RETINAL GANGLION CELLS D.Kumar, USA ; I.Charles, USA ; R.Krishnamoorthy, USA ; R.Roque, USA ; N.Agarwal, USA (*)		1180.00	429
1215	0 REGULATION OF PROLIFERATION AND SURVIVAL OF OCULAR NEURAL STEM CELLS I.Ahmad, USA (*)		1154.00	8375
1230	0 LUNCH		9015.00	8511

1330 - 1415 Hall***Poster Session 5***

Chair

205/ PO11

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	COMPERATIVE ASSESSMENT OF INTERFERON-INDUCTING ACTIVITY OF PARA-AMINOBENZOIC ACID AND POLI A:U IN RABBIT EYES S.Akbarova, Azerbaijan (*) ; P.Musayev Galbinur, Azerbaijan ; E.Tazulakhova, Russia ; O.Stroevea, Russia		1026.00	8162
0	THE TREATMENT OF TOXIC OPTICOPATHY WITH HIGH DOSES CORTICOSTEROIDS C.Bazarbaeva, Kyrgyzstan (*) ; M.Medvedev		1106.00	7511
0	METHYLPYRROLIDINONE CHITOSAN (MPC) AS POTENTIAL OCULAR PERMEATION ENHANCER: EVALUATION USING RABBIT CULTURED CORNEAL EPITHELIAL CELL LAYERS S.Burgalassi, Italy (*) ; D.Monti ; P.Chetoni ; M.Saettone		1087.00	8227

**Sunday 14 March**

1330 - 1415

Hall

**Poster Session 5**

Chair

205/ PO11

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	NIMESULIDE EYEDROPS: FORMULATION AND OCULAR PHARMACOKINETIC STUDIES P.Chetoni, Italy (*) ; S.Burgalassi, Italy ; D.Monti, Italy ; C.Sommani, Italy ; E.Boldrini, Italy ; M.Saettone, Italy		1086.00	1508
0	T-PA ENCAPSULATION IN LIPOSOMES FOR EXTRAVASCULAR ADMINISTRATION IN VENOUS THROMBOSIS S.Antimisiaris, Greece ; M.Tsilimbaris, Greece ; E.Christodoulakis, Greece (*) ; I.Naoumidi, Greece ; V.Panteleontidis, Greece ; I.Pallikaris, Greece		1121.00	8343
0	PHARMACOKINETIC INVESTIGATION OF PRR WITHIN THE EYE OF RABBITS FOLLOWING INTRAPERITONEAL INJECTION X.Deng, China (*) ; Q.Zhang, China ; S.Lin, China ; J.Yang, China ; M.Hu, China		1003.00	8084
0	COMPARATIVE BIOAVAILABILITY STUDIES WITH A NEW DRUG DELIVERY DEVICE D.M., Germany (*) ; L.A. ; S.A.		1095.00	2189
0	TRANSCORNEAL AND TRANSSCLERAL IONTOPHORESIS OF DEXAMETHASONE PHOSPHATE IN RABBITS USING DRUG LOADED HYDROGEL E.Eljarrat-Binstock, Israel ; J.Frucht-Pery, Israel ; F.Raiskup, Israel ; A.Domb, Israel (*)		1168.00	8437
0	DELIVERY OF GENTAMICIN TO THE RABBIT EYE USING DRUG-LOADED HYDROGEL IONTOPHORESIS E.Eljarrat-Binstock, Israel (*) ; J.Frucht-Pery, Israel ; F.Raiskup, Israel ; A.Domb, Israel		1173.00	8440
0	MICROEMULSION CONTAINING DEXAMETHASONE INTENDED TO TOPICAL OCULAR ADMINISTRATION S.Fialho (*) ; A.Silva-Cunha		1023.00	8161
0	DEXAMETHASONE IN BIODEGRADABLE IMPLANTS FOR INTRAOCULAR APPLICATION S.Fialho (*) ; A.Silva-Cunha		1024.00	8161
0	IONTOPHORETIC TREATMENT OF EXPERIMENTAL PSEUDOMONAS KERATITIS IN RABBIT EYE USING GENTAMICINE - LOADED HYDROGEL J.Frucht-Pery, Israel (*) ; F.Raiskup, Israel ; E.Eljarrat-Binstock, Israel ; A.Domb, Israel		1174.00	2983
0	CYCLOSPORINE-A LEVEL IN SERUM AFTER TOPICAL APPLICATION OF EYE DROPS FROM MODUSIK-A OFTENOTM J.Gonzalez, Mexico (*) ; V.Sanchez-Catellanos ; L.Baiza-Duran ; J.Quintana-Hau ; M.Lopez-Sanchez ; R.Tornero-Montaño		1040.00	8176
0	PHARMACOKINETIC STUDY OF TTP WITHIN THE EYE OF NEW ZEALAND WHITE RABBITS FOLLOWING INTRAPERITONEAL INJECTION M.Hu, China (*) ; X.Deng, China ; Q.Zhang, China ; S.Lin, China ; X.Chen, China		1001.00	8065
0	INHIBITION OF GROWTH FACTOR STIMULATED STAT3 BY AG490 IN HRPE CELLS P.Kothary, USA (*) ; M.Del Monte		1083.00	4684
0	SOLUBLE DRUG INSERTS FOR THE TREATMENT OF EYE DISEASES Y.Maychuk, Russia (*) ; A.Yuzhakov ; D.Maychuk ; G.Khromov		1029.00	8169
0	NOVEL ANTIOXIDANT HISTOCHROME IN THE TREATMENT OF CORNEAL INFLAMMATION AND DYSTROPHIES Y.Maychuk, Russia (*) ; L.Larina ; V.Pozdnjakova ; D.Maychuk		1031.00	8169
0	NOVEL SOLUBLE OPHTHALMIC INSERTS WITH CYCLOSPORIN A D.Maychuk, Russia (*)		1030.00	8170
0	POSSIBILITIES OF APPLYING EYE DROPS BASED ON HYALURONIC ACID IN CONTACT LENS PRACTICE A.Kivaev, Russia ; S.Fidler ; A.Moussina (*)		1189.00	8461
0	PASSIVE DIFFUSION OF CYCLOSPORINE-A ACROSS THE CORNEA COMPARING SOPHISEN <sup>TM</sup> VERSUS OLIVE OIL AS VEHICLES J.Quintana-Hau, Mexico (*) ; M.Lopez-Sanchez ; E.Cruz-Olmos ; J.Gonzalez ; L.Baiza-Duran ; V.Sanchez-Castellanos		1039.00	8192

**Sunday 14 March**1330 - 1415 Hall**Poster Session 5**

Chair

205/ PO11

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	EMULSIFICATION OF SILICONE OIL IN THE HUMAN EYE J.Schmidt, Germany (*) ; S.Mennel, Austria ; C.Meyer, Germany ; S.Hörle, Germany		1156.00	8383
0	ACCUMULATION OF POLYION COMPLEX MICELLE TO EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION IN RATS F.Tasaka, Japan (*) ; R.Ideta, Japan ; Y.Yanagi, Japan ; Y.Tamaki, Japan ; A.Harada, Japan ; K.Kataoka, Japan		1058.00	8280
0	NOVEL PROTECTIVE EFFECT OF CQQ, A NATURAL COMPOUND, ON RETINAL DAMAGE INDUCED BY N-METHYL-N-NITROSOUREA IN RATS J.Yang, China (*) ; S.Lin, China ; J.Chen, China ; Y.Zhang, China ; M.Hu, China		1004.00	8085
0	LASER TARGETED DRUG DELIVERY - EFFICACY IN EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION AND SYSTEMIC SAFETY IN DOGS R.Zeimer, USA (*) ; M.Goldberg, USA ; .D'Anna, USA ; R.Rush, USA		1134.00	6345

1330 - 1415 Hall**Poster Session 6**

Chair

210/ PO9

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	EFFECTS OF BUPIVACAINE AND LIDOCAINE ON THE CORNEAL ENDOTHELIUM: AN ULTRASTRUCTURAL COMPARATIVE STUDY C.Akarsu, Turkey (*) ; A.Bayramoglu, Turkey ; A.Ergin, Turkey ; H.Celik, Turkey ; P.Taner, Turkey ; D.Demiryurek, Turkey		1017.00	8139
0	DYNAMIC LIGHT SCATTERING QUANTIFIES THE EFFECT OF MICROPALSMIN PHARMACOLOGIC VITREOLYSIS R.Ansari, USA (*) ; K.Suh, USA ; J.Sebag, USA		1114.00	8304
0	COMPARISON OF MACULAR THICKNESS MEASUREMENT IN HEALTHY PATIENTS WITH OPTICAL COHERENCE TOMOGRAPHY 3 AND RETINAL THICKNESS ANALYZER N.benhamou, Israel (*) ; O.segal ; A.Kaplan-messas ; B.Serebryani ; I.avni		2021.00	1193
0	MAPPING DIABETIC MACULAR EDEMA. COMPARISON BETWEEN STEREOFUNDUS PHOTOGRAPHY, RTA AND OCT R.Bernardes, Portugal (*) ; J.Figueira, Portugal ; C.Lobo, Portugal ; J.Cunha-Vaz, Portugal		1096.00	1201
0	RED DOTS COUNTING IN COLOUR FUNDUS PHOTOGRAPHIES OF TYPE 2 DIABETIC PATIENTS R.Bernardes, Portugal (*) ; L.Duarte, Portugal ; T.Torrent-Solans, Portugal ; E.Almeida, Portugal ; J.Cunha-Vaz, Portugal		1099.00	1201
0	EFFICACY OF APRACLONIDINE DROPS IN PATIENTS UNDERGOING ANTERIOR SEGMENT LASER THERAPY S.Chaturvedi (*) ; A.Mehrotra ; S.Mittal ; H.Bahadur		1002.00	8083
0	USE OF CYTOCHROME-C-PEROXYDASE TO REDUCE THE REEPITHELIZATION TIME: COMPARING STANDARD RESIDENTIAL POPULATION AND ARMY PERSONNEL IN PEACE KEEPING OPERATION F.Marmo, Italy ; L.Marino, Italy ; F.Cicirello, Italy (*)		1133.00	1891
0	COMPARISON OF THE EFFECTS OF VARIOUS INTRAOCULAR IRRIGATION SOLUTIONS ON CORNEAL EDEMA AFTER CATARACT SURGERY D.Gharabaghi, Iran (*) ; H.Nazari		1042.00	8195
0	TO EVALUATE THE EFFICACY OF OFTAGEL IN DRY EYE PATIENTS A.Hovakimyan, Armenia (*) ; S.Hakobyan ; R.Grigoryan ; A.Malayan		1107.00	8299
0	A NEW RETINAL VESSEL OXIMETER: SENSITIVITY AND REPRODUCIBILITY L.Kagemann, USA (*) ; A.Harris ; R.Dinn ; E.Rechtman ; C.Jonescu-Cuypers		1065.00	8204

**Sunday 14 March**

1330 - 1415

Hall

**Poster Session 6**

Chair

210/ PO9

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	INSERTS FOR DRY EYE SYNDROME TREATMENT C.Lohmann, Germany (*) ; C.Koelwel, Germany ; B.Gabler, Germany ; A.Goeperich, Germany		1080.00	90
0	INTRAVITREAL INJECTION OF TRIAMCINOLONE ACETONIDE AS TREATMENT OF CHRONIC UVEITIC CME (PRELIMINARY RESULTS) S.Maca, Austria (*) ; C.Abela-Formanek ; T.Barisani-Asenbauer		1125.00	8346
0	OCT FINDINGS IN PATIENTS WITH LOCALIZED SCOTOMA ASSESSED WITH SLO MICROPERIMETRY M.Menke, USA (*) ; E.Sato ; F.Van De Velde ; G.Feke		1103.00	8286
0	CLINICAL EXPERIENCE WITH OFTAGEL IN THE POST-RECONSTRUCTION PERIOD OF INJURED EYELIDS T.Pancheva, Bulgaria (*) ; R.Hristova		2002.00	8475
0	LONG TERM USE OF A PRESERVATIVE-FREE 0.1% DEXAMETHASONE (ETACORTILEN) AFTER PHOTOREFRACTIVE KERATECTOMY (PRK) P.Russo, Italy (*) ; M.Lazzarotto, Italy ; A.Favero, Italy ; M.Tomasello, Italy ; C.Sforzi, Italy ; G.Milazzo, Italy ; V.Papa, Italy ; A.Caporossi, Italy		1123.00	8345
0	CATARACTS ASSOCIATED WITH QUETIAPINE (SEROQUEL(R)) D.Rajguru, USA (*) ; F.Fraunfelder		2025.00	8491
0	TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE CONJUNCTIVA B.Schultz, USA (*) ; C.Shields, USA ; A.Mashayekhi, USA ; J.Shields, USA		1077.00	8212
0	USE OF DERINAT IN TREATMENT OF CORNEAL DISEASES O.Sugonyaeva, Russia (*) ; E.Egorov		1084.00	8221
0	USING OF CHITOSAN BIOGEL VASNA FOR THE TREATMENT OF THE EXPERIMENTAL DRY EYE T.Tajibaev, Kyrgyzstan (*)		1128.00	8348
0	EVALUATION OF LENS TRANSPARENCY USING SCHEIMPFLUG PHOTOGRAPHY AND SLIT LAMP BIOMICROSCOPY IN RAT M.Verdugo, USA (*) ; D.Baltrukonis, USA ; A.Ryan, USA ; J.Fortner, USA		1126.00	7556
10	EFFICACY AND SAFETY OF TOPICAL CYCLOSPORINE A IN MANAGEMENT OF ALLOGRAFT REJECTION IN HIGH RISK POST KERATOPLASTY PATIENTS; AN INDIAN STUDY A.Khuteta, India (*) ; P.Mathur, India ; A.Kothari, India ; S.Kaushal, India		2029.00	8432

1415 - 1500

Hall

**Poster Discussion 5**

Chair

215/ PO12

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	POSTER DISCUSSION WILL INCLUDE POSTERS FROM FOLLOWING BOARDS:		9457.00	8511
1500	COFFEE BREAK		9018.00	8511

**Sunday 14 March****1415 - 1500** **Hall****Poster Discussion 6***Chair*

220/ PO10

Time	Title	Poster Board Number	Abstract Number	Reference IC
0	POSTER DISCUSSION WILL INCLUDE POSTERS FROM FOLLOWING BOARDS:			8511
			9456.00	
1500	COFFEE BREAK			8511
			9017.00	

**1530 - 1615** **Hall****Retina Other***Chair*

225/ OR35

Time	Title	Poster Board Number	Abstract Number	Reference IC
1530	ARE STATINS OR ANTI-HYPERTENSIVES PROTECTIVE OF AMD? E.Friedman, USA (*)		1090.00	6919
1539	GENISTEIN SOY BASED TKI FOR RETINAL PROTECTION E.De Juan, Jr., USA (*) ; M.Mahmoud, USA ; M.Cooney, USA ; J.Cao, USA ; R.Grebe, USA		1146.00	8086
1548	RETINAL PROTECTION S.Whitcup, USA (*)		1186.00	6275
1557	THE ROLE OF NUTRITION AND SUPPLEMENTATION IN AGE-RELATED MACULAR DEGENERATION M.Cooney, USA (*)		2013.00	8481
1606	PHARMACOLOGIC THERAPY IN RETINOPATHY OF PREMATURITY M.Trese, USA (*)		1093.00	7372

**1530 - 1700** **Hall****Immunology Of The Ocular Surface***Chair*

230/ OR31

Time	Title	Poster Board Number	Abstract Number	Reference IC
1530	IMMUNE BASED THERAPIES IN SKIN DISEASE P.Walker, USA (*)		1157.00	7758
1545	THE PROOF FOR THE IMMUNE APPROACH TO DRY EYE DISEASE M.Stern, USA (*)		1078.00	6014
1600	EYE ASSOCIATED LYMPHOID TISSUE (EALT) AND THE OCULAR SURFACE E.Knop, Germany (*) ; N.Knop, Germany		1075.00	8057
1615	CLINICAL APPROACH TO DIAGNOSING IMMUNE MECHANISMS OF OCULAR SURFACE DISEASE J.Smith, USA (*) ; G.Reed, USA ; S.Vitale, USA ; C.Chan, USA		2016.00	8134
1630	IMAGING OF LEUKOCYTE ROLLING AND EXTRAVASATION IN HUMAN TISSUES USING IN VIVO CONFOCAL MICROSCOPY T.Tervo, Finland (*) ; M.Helinto, Finland ; J.Kirveskari, Finland ; E.Savilahti, Finland ; J.Moilanen, Finland ; R.Renkonen, Finland		1063.00	6050
1645	PANEL DISCUSSION			8511
			9340.00	